Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway target

[News]

Patients with HER2-positive cancers can have dramatic responses to HER2-targeted drugs but eventually develop resistance to the agents. With that problem in mind, Fox Chase Cancer Center researchers are testing a novel type of antibody called MM-111 in patients with HER2-positive disease who have progressed on standard therapy.

More... (http://www.news-medical.net/news/20100605/Fox-Chase-Cancer-Center-announces-first-in-human-bi-specific-HER2HER3-pathway-targeting-antibody.aspx)